Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cetuximab-IRDye800
- Development stage
- Unknown
- Lead developer
- Eben Rosenthal
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Cetuximab-IRDye800 is a near-infrared (NIR) fluorescently labeled monoclonal antibody developed as an optical imaging agent for intraoperative surgical navigation. It consists of the chimeric IgG1 monoclonal antibody cetuximab, which targets the epidermal growth factor receptor (EGFR), covalently conjugated to the NIR dye IRDye800CW. EGFR is overexpressed in over 90% of head and neck squamous cell carcinomas (HNSCC). When administered intravenously prior to surgery, the agent binds to EGFR-expressing tumor cells, allowing real-time visualization of tumor margins and metastatic lymph nodes using specialized NIR imaging systems. This molecular imaging approach aims to improve the precision of surgical resection and cancer staging by differentiating malignant tissue from normal surrounding structures.
- Other names
- IRDye800CW-cetuximabIRDye-800CW-cetuximabIRDye 800CW-cetuximab
02
Targets
EGFRvIII (Epidermal growth factor receptor variant III)EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on Cetuximab-IRDye800.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cetuximab-IRDye800.